FGF21 – Medxy AI

HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy

By MedXY 09/20/2025

A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatment.

Clinical Updates Gastroenterology Internal Medicine news Specialties

Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results

By MedXY 08/02/2025

Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled trial.